TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04285918

Intervention type: PROCEDURE
Intervention: Percutaneous device closure
Description: If there is no relevant AF detected for 6 months during intermittent follow-up or ICM, device closure of PFO is recommended for high-risk PFOs but is decided ultimately at the discretion of the attending physician. If there is any relevant AF identified from ICM or other modalities during follow-up, adequate secondary prevention with anticoagulants should be carried out. All this process and decision making should be a part of routine clinical practice.
Study: NCT01477021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1-specific T cells
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04502615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sand
Description: sand surface

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: artificial grass
Description: grass surface

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: firm ground
Description: firm surface
Study: NCT01604746

Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Ross River Virus (RRV) Vaccine
Description: Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study.
Study: NCT00662961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periosteum
Description: Periosteum fixation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone
Description: Bone tunnel fixation
Study: NCT02160067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second generation BTDS patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second generation BTDS patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: First generation BuTrans patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: First generation BuTrans patch
Study: NCT00960583

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine follow-up
Description: Advice to stay active
Study: NCT01172379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: Experimental 1 Drug: E2007~0.5 mg 1 tablet per day
Study: NCT03026101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Intra-arterial adminstration to dilate external carotid artery branches to replicate migraine pain
Study: NCT01115192

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A
Description: Blephacura is a solution with liposomes and used for cleaning of the eye lid to treat blepharitis
Study: NCT01172379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: Experimental 2 Drug: E2007~1.0 mg 1 tablet per day
Study: NCT00482222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study: NCT01172379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: Drug: E2007~2.0 mg 1 tablet per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo 1 tablet per day
Study: NCT06008548

Intervention type: PROCEDURE
Intervention: TACE
Study: NCT03246438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colonoscopy only
Description: Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to schedule colonoscopy.
Study: NCT00482222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: study of socioeconomic and demographic variables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study of socioeconomic and demographic variables

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT02556515

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interpositional arthroplasty (Burton-Pellegrini procedure)
Description: Burton-Pellegrini procedure
Study: NCT03246438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colonoscopy outreach + mailed FIT follow-up
Description: Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to either schedule colonoscopy or to complete the enclosed mailed FIT kit.
Study: NCT02466880

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: A 15-30 minute diabetes self-management session. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
Study: NCT03158675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fractional carbon dioxide(CO2) laser
Description: -Fractional CO2 laser: Laser sessions will be performed at half month interval and it will be used with a wave length of 10,600nm.
Study: NCT02556515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total joint replacement
Description: Total joint replacement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elektra prosthesis
Description: Elektra prosthesis
Study: NCT00865891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine Extended Release tablets 60 mg, single dose
Description: A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADALAT® CC Extended Release Tablets 60 mg
Description: B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under fasting conditions
Study: NCT01714102

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo manufactured to mimic resveratrol tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol
Description: Resveratrol PO BID for 30 days
Study: NCT03246438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colonoscopy + Mailed FIT outreach and follow-up
Description: Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line OR complete the enclosed mailed FIT kit. Subjects who have not completed FIT or scheduled colonoscopy within 4 weeks will be receive a reminder letter to either schedule colonoscopy or complete the mailed FIT kit previously sent.
Study: NCT01476436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate dietary advice
Description: Dietary advice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continue usual diet
Description: Dietary advice
Study: NCT03158675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: Topical corticosteroid will be applyed twice weekly on both sides for 4 months.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultraviolet B narrow band
Description: Ultraviolet B narrow band will be performed (wave length ranged from 300 to 320nm).The sessions will be performed twice weekly for 4 months.
Study: NCT02609256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic infarct tissue aspiration
Description: The patient posed supine position to expose local skin and puncture point was located at 6.5 cm behind the hairline of the lesion side, and 5.0 cm lateral of midline. After routine skin preparation and disinfection, 5% lidocaine 2-5 ml was injected for local anesthesia. The skin was cut to expose periosteum by a scalpel. After skull was vertically drilled through with a 6mm diameter hole, a sterile tube with a needle in tube was put about 8 cm into centrum semiovale. The needle was put out and about 50ml necrosis brain tissue was aspirated by a 20 ml syringe. The tube was fixed into the skin about 2 cm after subcutaneous tunnel, and connected to the drainage bag. Surgical area was sterilized and wrapped by sterile gauze bandage.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Medical therapy
Description: osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical therapy
Description: osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc
Study: NCT01476436

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continue usual diet
Description: Dietary advice
Study: NCT02753725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: The intervention arm will comprise Fentanyl given at a dose of one microgram per kilogramme body weight administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed.
Study: NCT01467622

Intervention type: PROCEDURE
Intervention: Chest tube removal
Description: Chest tube removal on the basis of local recommendations for postoperative chest tube management
Study: NCT02753725

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose per body weight,administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed
Study: NCT00736073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: one dose of aprepitant (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one dose of placebo (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
Study: NCT03566212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Syringe
Description: local anesthesia was administered in first group using Conventional syringe

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Camouflage Syringe
Description: local anesthesia was administered in second group using Camouflage syringe
Study: NCT02662478

Intervention type: PROCEDURE
Intervention: Laparoscopic Surgery
Description: Mid-point between the xiphoid and umbilicus was used to the entrance site of the telescope. Open trocar insertion was used in patients with history of open upper abdominal surgery; otherwise Veress needle established CO2 insufflations. The number, size and entry points of the other trocars were tailored according to the tumor location and size. In general, 2 to 4 additional trocars were used. All specimens were taken out of the abdomen through a suprapubic transverse incision in a sterile bag. Resection technique was determined by the size, number, location of the lesion, and surgical anatomy of the stomach. Lymph node dissection was not done as it is unnecessary.
Study: NCT04845295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training
Description: Both experimental groups performed two exercises to target elbow flexor and knee extensor muscles: biceps curl on a Scott bench and parallel barbell squat, respectively. All sessions were performed at the same time (13-15 h), with a minimum 48 h rest between sessions on the same days during the week. For both groups, the intensity of load (1RM%) and number of sets were as follows: in the first three weeks the subjects exercises with ̴ 60% of 1RM in 3 sets, while during the next four weeks the load was set at ̴ 70% of 1RM in 4 sets. All repetitions were performed until muscular failure. The pause between sets was 2 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training
Description: Both experimental groups performed two exercises to target elbow flexor and knee extensor muscles: biceps curl on a Scott bench and parallel barbell squat, respectively. All sessions were performed at the same time (13-15 h), with a minimum 48 h rest between sessions on the same days during the week. For both groups, the intensity of load (1RM%) and number of sets were as follows: in the first three weeks the subjects exercises with ̴ 60% of 1RM in 3 sets, while during the next four weeks the load was set at ̴ 70% of 1RM in 4 sets. All repetitions were performed until muscular failure. The pause between sets was 2 minutes.
Study: NCT01933386

Intervention type: DEVICE
Group type: OTHER
Intervention: SoundBite
Description: Non-surgical removable bone conduction device via the teeth.

Intervention type: DEVICE
Group type: OTHER
Intervention: SoundBite
Description: Non-surgical removable bone conduction device via the teeth.
Study: NCT03477786

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: drug adjustment and behavioral modification
Description: anti-hypertension drug prescription by physician and case management by health educator

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: drug adjustment and behavioral modification
Description: anti-hypertension drug prescription by physician and case management by health educator
Study: NCT03820791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of a poster in patients' rooms
Description: Patients and their caregivers will be exposed to the poster for one month
Study: NCT03941743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02328976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional Magnetic Resonance Imaging (fMRI)
Description: both chronic and episodic patients with migraine have a specific functional Magnetic Resonance Imaging (fMRI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional Magnetic Resonance Imaging (fMRI)
Description: both chronic and episodic patients with migraine have a specific functional Magnetic Resonance Imaging (fMRI)
Study: NCT00183456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-oriented intervention
Description: The peer-oriented intervention program emphasized social identity and the goals of protecting family and community. The peer program also trained participants to provide HIV/STD education to their peers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group cognitive behavioral therapy (CBT)
Description: Group CBT will focus on teaching ways to modify thoughts and behaviors associated with risky sexual behaviors.
Study: NCT06645340

Intervention type: OTHER
Group type: OTHER
Intervention: This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length
Description: This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length, and routine laboratory parameters.

Intervention type: OTHER
Group type: OTHER
Intervention: This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length
Description: This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length, and routine laboratory parameters.
Study: NCT03288298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luteolin
Description: flavonoid natural extract

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nano-luteolin
Description: nanoparticles of luteolin
Study: NCT01256541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kristalose
Description: The dosing regimen of Kristalose will be nine 20-gram doses (one dose every 30 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
Study: NCT04375306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFR guided CABG
Description: All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the experimental arm the decision to revascularize will be based on RFR.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angio guided CABG
Description: All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the control arm the RFR values will be blinded to the cardiothoracic surgeon.
Study: NCT01188850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3100
Description: DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
Study: NCT01370317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1029
Description: Five (5) X 100 mg capsules, orally, once daily for 28 days
Study: NCT01115192

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B
Description: Diluted Baby Shampoo is used for cleaning of the eye lid to treat blepharitis
Study: NCT02228616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: During the 12-week treatment phase of the study, the daily dose of 1 tablet of 2-mg prucalopride will be administrated orally before breakfast.
Study: NCT00005973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-214662
Description: Given IV
Study: NCT02228616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Description: Optimized dose of PEG will be administrated for 13 weeks (1 week run-in+12 weeks intervention).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Optimized dose of Lactulose will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
Study: NCT01149954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
Study: NCT00303589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta-lactam
Description: 750mg iv q8h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta-lactam
Description: 1500mg iv q8h
Study: NCT03670420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical honey
Description: The investigators use Medihoney®, a medical honey released by the DermaSciences.
Study: NCT04469829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: standard doses of secukinumab for psoriasis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 15 mg/week
Study: NCT01568528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: OT intervention will be administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The PBO/control will consist of the OT vehicle only delivered as 3 puffs of saline per nostril for a total of 6 puffs. Each puff contains 0.1 ml in volume, so the total delivered will be 0.6 ml intranasally.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants who have no psychiatric diagnosis and will be controls for this project. These controls will NOT receive oxytocin or PBO. They will only receive psychiatric screening interview, MCCB Consensus Cogntive Battery assessment, urine drug screen, vision testing, and the three social cognition tasks.
Study: NCT01849887

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow-derived mesenchymal stem cells
Description: bone marrow-derived mesenchymal stem cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03454009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal hygiene intervention
Description: hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer.
Study: NCT00005973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03364439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment plan
Description: R-CHOP14 or R-CHOP21 for 6 cycles Restaging after 2, 4, 6 cycles Consolidation therapy with RT (36 Gy) if PET positive (PET after 6 R-CHOP cycles)
Study: NCT03176017

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ejaculatory sparing TUIP
Description: The bladder neck will be incised and vaporized at the 5 or 7-o'clock position. The incision will start near the ureteral orifice and carry downward to about 0.5-1.0 cm proximal to the verumontanum

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional TUIP
Description: the bladder neck will be incised by Collins knife at the 5 or 7-o'clock position till the verumontanum.